Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies

PHASE1,PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped The study was stopped after interim analysis indicated that overall result was not sufficient to satisfy per-protocol criteria to move forward in metastatic, castration-resistant prostate cancer (mCRPC) and non-small cell lung cancer (NSCLC) cohorts.

Conditions

Prostate Cancer
Non-small Cell Lung Cancer

Interventions

DRUG: Isatuximab SAR650984
DRUG: Cemiplimab REGN2810

Sponsor

Sanofi